GLP-1 for Menopause Weight Gain: What the Research Shows

The weight changed, but your effort did not

You are doing the things that used to work. Maybe you are eating the way you always have, walking most days, watching portions, skipping the second glass of wine. And the weight is climbing anyway, settling in around your middle in a way it never did before. If that describes you, the first thing to understand is that you are not imagining it, and it is not a discipline problem.

Weight gain in your late thirties, forties, and fifties is one of the most common experiences women have, and it lines up with a specific biological event: the menopause transition. Your effort did not decrease. Your biology changed. This page explains what actually shifts in your body during perimenopause and menopause, what the research says about weight management in this stage of life, and how to think about whether GLP-1 medication is a reasonable option for your situation.

One thing to be clear about up front. GLP-1 medications are not approved to treat menopause or perimenopause. They are prescribed for weight management in eligible patients. Nothing on this page describes them as a hormone treatment or a fix for menopause symptoms.

Midlife weight gain is biology, not willpower

Up to 70% of women gain weight during the menopause transition. That is not a coincidence, and it is not a collective failure of willpower. It is the predictable result of hormonal and metabolic changes that happen to nearly everyone during this window.

Research published in the journal Climacteric describes weight gain at menopause as driven by a combination of aging and the hormonal shifts of the transition, not by women suddenly eating more or moving less.^[1] In other words, the standard advice to “just eat less and move more” is aimed at a problem you may not actually have. You can hold your habits steady and still gain weight, because the machinery underneath those habits is changing.

Naming this correctly matters, because you have probably been told, directly or by implication, that the weight is your fault. The science does not support that framing. The weight is a symptom of a physiological transition. Understanding the mechanism is the first step to addressing it in a way that actually fits the problem.

What actually changes in your body during the menopause transition

Several distinct changes stack on top of each other during perimenopause and menopause. Each one nudges your body toward storing more and burning less. Together, they explain why the same routine produces a different result. If you are still getting your period, these shifts are already underway during the transition; our companion guide on GLP-1 in perimenopause covers the still-cycling window and the contraception and fertility considerations that come with it.

Estrogen decline shifts where you store fat. As estrogen falls, your body tends to move fat storage away from the hips and thighs and toward the abdomen, including deeper visceral fat that wraps around your organs. A study in the International Journal of Obesity that followed women through the transition documented increased visceral fat during this window, independent of overall weight.^[2] This is why the weight can feel like it is landing somewhere new. It is.

You lose muscle, and muscle is metabolically active. The menopause transition is associated with a measurable loss of lean muscle mass. Research from the Study of Women’s Health Across the Nation (SWAN), published in JCI Insight, tracked declines in lean mass alongside gains in fat mass as women moved through the transition.^[3] Muscle burns more energy at rest than fat does, so losing muscle quietly lowers the number of calories your body uses just to keep running.

Your resting energy expenditure slows. The same research that documented rising visceral fat also found a decrease in energy expenditure during the menopausal transition.^[2] This is not the dramatic “broken metabolism” of internet myth. It is a real, modest downshift in how many calories your body burns, and it compounds with the muscle loss above.

Appetite, sleep, and food noise change too. Sleep disruption is common in perimenopause, and poor sleep is linked to increased appetite and stronger cravings. The hormonal shifts of this stage can also intensify the intrusive, hard-to-ignore food thoughts you may know as “food noise.” None of this is a character flaw. It is your biology recalibrating, and it makes the old approach harder to sustain even when you are trying just as hard as before.

Where GLP-1 medications fit, and where they do not

Here is the honest boundary. GLP-1 medications are not a treatment for menopause. They do not replace estrogen, they are not hormone therapy, and they are not expected to help with hot flashes, night sweats, or mood changes. What they do is act on appetite and digestion.

GLP-1 medications reduce appetite and slow how quickly your stomach empties, which for many people quiets the constant food noise and makes a smaller, steadier intake feel manageable rather than like a fight. If your appetite signaling and metabolism have shifted against you, that mechanism addresses one specific piece of the picture: the intake side of an equation that biology has tilted.

That is the accurate way to frame it. A GLP-1 is a weight management tool a provider may consider as part of a broader plan that includes nutrition and, importantly for this stage of life, resistance training to protect the muscle and bone you do not want to lose. It is not a menopause treatment, and it is not a standalone fix.

What the research shows

The large clinical trials behind GLP-1 medications were conducted with FDA-approved branded products, and what they actually tested matters.

In the STEP 1 trial, published in the New England Journal of Medicine, adults with overweight or obesity who received semaglutide for weight management lost significantly more weight than those on placebo over 68 weeks, alongside lifestyle support.^[4] In the SURMOUNT-1 trial, also in the New England Journal of Medicine, adults with obesity who received tirzepatide for weight management saw substantial reductions in body weight compared with placebo.^[5] These trials enrolled large numbers of women in the age range where the menopause transition occurs, so this population was well represented in the data, even though the trials were not designed specifically to study menopause.

What the trials do not tell you is exactly what will happen for you. Results vary by individual and depend on many factors, including your starting point, your health history, and the nutrition and activity plan around the medication. Your provider will help you understand what a realistic outcome looks like for your situation.

One critical clarification about what these findings apply to. Every result described above comes from FDA-approved branded products. Transformation Health works with compounded semaglutide and tirzepatide. Compounded medications are not FDA-approved. They have not been independently evaluated by the FDA for safety, efficacy, or quality, and they may differ from branded versions in formulation, purity, or potency. The trial data is evidence about the branded medications tested, not a promise about a compounded product.

GLP-1 medications are not hormone therapy

Because this comes up so often, here it is directly. If your main concern is menopause symptoms, hot flashes, sleep disruption, mood changes, vaginal dryness, then a GLP-1 medication is not the tool for that. Hormone therapy is one of the options a provider might discuss for symptom management, and that is a separate clinical conversation.

Many women in midlife are managing both things at once: menopause symptoms and midlife weight gain. It is possible to be evaluated for weight management while also working with a provider on symptoms. If you are already on hormone replacement therapy, that is relevant information for any provider considering a GLP-1, and there is no known interaction that automatically rules out using both. We go deeper on this in our guide to hormone therapy and GLP-1 medications. If you still rely on oral contraception rather than hormone therapy, mention that too, since GLP-1 medications can change how your body absorbs oral birth control.

Who may be a candidate

Not every woman in midlife is a candidate for GLP-1 treatment, and eligibility is a clinical judgment, not an automatic yes. Your provider will look at several factors.

GLP-1 medications for weight management are generally considered for adults with a BMI of 30 or higher, or 27 or higher with a weight-related condition such as high blood pressure, prediabetes, or high cholesterol. Being in perimenopause or menopause does not by itself qualify or disqualify you. It is part of the context your provider considers, not the criterion.

You do not have to be diabetic. GLP-1 medications are widely used for weight management in people without diabetes, and among adults using them for weight management, most are women. If you have been putting off looking into this because you assumed it was only for diabetics, that assumption is worth revisiting. We cover it directly in Can I Get GLP-1 If I’m Not Diabetic?.

The most useful way to think about it: you may be a candidate, and a licensed provider makes the final determination after reviewing your health history. Some women will be good candidates. Some will need to address other health factors first. Some will not be candidates at all. That is what the evaluation is for.

How Transformation Health evaluates midlife weight gain

When you complete an assessment with Transformation Health, your information goes to an independent, licensed provider. That provider reviews your health history, including where you are in the menopause transition, your current medications (including hormone therapy if you use it), your labs where available, and your goals.

The provider makes a clinical judgment about whether GLP-1 treatment for weight management is appropriate for your specific situation. If it is, your medication is prepared by a licensed US compounding pharmacy. Because muscle and bone loss are real concerns in this stage of life, our coaching emphasizes protein intake and resistance training alongside the medication, so the weight you lose is more likely to be fat rather than the muscle you want to keep. Our companion guide on perimenopause nutrition on GLP-1 medications walks through how to eat for this stage.

The goal is not lifelong medication. It is to use the medication as a bridge that quiets food noise and makes new habits possible, then to build the nutrition and strength foundation that lets you eventually reduce or step off it.

Residents of Arkansas, Delaware, Mississippi, New Mexico, Rhode Island, Washington DC, and West Virginia are required by state law to complete a live video consultation before a prescription can be written.

What to know about our medications

Transformation Health works exclusively with US-based, licensed compounding pharmacies. Our semaglutide and tirzepatide are compounded medications, not FDA-approved branded products.

Here is what that means in plain terms. Semaglutide and tirzepatide are the active ingredients in certain FDA-approved branded medications. Compounded versions are prepared by a licensed compounding pharmacy and are not FDA-approved. They have not been independently evaluated by the FDA for safety, efficacy, or quality, and they may differ from branded versions in formulation, purity, or potency. Any clinical trial data on safety or efficacy applies to the branded products, not to compounded versions.

Compounded semaglutide is available as an injectable or an oral option. Compounded tirzepatide is injectable. Our microdose GLP-1 program is also injectable. Your provider will recommend which medication, dose, and delivery method is appropriate for you.

Our pricing is all-inclusive. Your monthly fee covers medication, lab work (through Quest or Labcorp), provider care, and access to our coaching team. No hidden fees. You can cancel anytime.

How to get started

Get a GLP-1 Prescription Complete a free online assessment. Tell us about your weight history, where you are in the menopause transition, your current medications, and your goals. An independent, licensed provider reviews your information and responds to let you know whether treatment is appropriate for you. If it is, your medication ships within days.

You can also review our GLP-1 Eligibility Guide if you want to understand the full qualification criteria before starting an assessment.

If PCOS or insulin resistance is also part of your history, our guide on GLP-1 and PCOS covers another hormone-driven weight condition GLP-1 medications are used to address, one of several topics in our guide to GLP-1 and specific health conditions.

Citations

[1] Davis SR, Castelo-Branco C, Chedraui P, et al. “Understanding weight gain at menopause.” Climacteric. 2012;15(5):419-429. PMID: 22978257.

[2] Lovejoy JC, Champagne CM, de Jonge L, Xie H, Smith SR. “Increased visceral fat and decreased energy expenditure during the menopausal transition.” International Journal of Obesity. 2008;32(6):949-958. PMID: 18332882.

[3] Greendale GA, Sternfeld B, Huang M, et al. “Changes in body composition and weight during the menopause transition.” JCI Insight. 2019;4(5):e124865. PMID: 30843880.

[4] Wilding JPH, Batterham RL, Calanna S, et al. “Once-Weekly Semaglutide in Adults with Overweight or Obesity.” New England Journal of Medicine. 2021;384(11):989-1002. PMID: 33567185.

[5] Jastreboff AM, Aronne LJ, Ahmad NN, et al. “Tirzepatide Once Weekly for the Treatment of Obesity.” New England Journal of Medicine. 2022;387(3):205-216. PMID: 35658024.